Cytonics
Developing diagnostics and therapeutics for osteoarthritis
Overview
Platform
Dealmaker Securities
Start Date
01/03/2023
Close Date
04/01/2023
Min. Goal
$25,000
Max. Goal
$1,951,220
Min. Investment
$1,000
Security Type
Equity - Preferred
Series
Series C
Funding Type
RegCF
Price Per Share
$2.30
Pre-Money Valuation
$58,915,995
Location
Jupiter, Florida
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Low
Capital Intensity
High
Cytonics, with a valuation of $58.9 million, is raising funds on Dealmaker Securities. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. The company has a strong IP portfolio with 22 issued US and international patents. Gaetano Scuderi founded Cytonics Corporation in July 2006. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.9 million. The campaign proceeds will be used for GMP manufacturing of CYT-108, phase 1 human clinical trial, and working capital.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$307,500 |
$591,056 |
|
COGS |
$2,205,358 |
$503,906 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-22,544,189 |
$-995,850 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$967,757 |
$537,354 |
|
Accounts Receivable |
$341,193 |
$283,676 |
|
Total Assets |
$1,756,758 |
$1,466,746 |
|
Short-Term Debt |
$554,929 |
$2,400,661 |
|
Long-Term Debt |
$0 |
$107,502 |
|
Total Liabilities |
$554,929 |
$2,508,163 |
Financials as of: 01/03/2023
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Cytonics | 04/01/2023 | Dealmaker Securities | $58,915,995 | $0 | Equity - Preferred | Active | RegCF |
| Cytonics | 10/14/2022 | SeedInvest | $58,915,996 | $2,633,766 | Equity - Preferred | Funded | RegCF / RegD 506(c) |
| Cytonics | 04/30/2021 | SeedInvest | $46,701,000 | $4,667,638 | Equity - Preferred | Funded | RegA+ |
| Cytonics | 05/18/2019 | SeedInvest | $32,400,000 | $494,344 | Convertible Note | Funded | RegCF / RegD 506(c) |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
